Axycis (cisplatin)

Where it stands

Axycis (cisplatin), from Avyxa Holdings, LLC, is recorded as approved in the US. The FDA approval milestone is dated 2026-10-29 and is sourced as official. The application is NDA220748, and the dosage form is recorded as liquid.

The records leave several fields empty: therapeutic area, indication, and CHMP opinion date. The CHMP field is blank, which is consistent with a US-only record, but the records do not say whether any EU filing exists. Nothing here describes the approved indication, so this analysis cannot say which patients or tumour types the label covers.

Regulatory pathway and designations

The only designation recorded is "New formulation or manufacturer". The FDA milestone uses the same wording. This tells us the approval relates to a new formulation or a new manufacturer of an established active substance, not a new molecular entity. The records do not say which of the two applies, and they do not give any detail on the formulation beyond "liquid".

The records do not state the application pathway (for example, whether it relied on existing literature or reference product data), the review timeline, or whether any expedited program applied. They also show no orphan, priority review, or other special designations. These points should be confirmed from the FDA approval documents and the label before any conclusions are drawn.

Safety and pharmacovigilance

The records contain no safety information. There is no boxed warning, contraindication, adverse-event data, risk management requirement, or postmarketing commitment in the data provided.

Cisplatin is a long-established cytotoxic agent, so the full prescribing information for Axycis should be reviewed directly. Points to check include any differences in strength, concentration, preparation and handling, and storage compared with other cisplatin products. Such differences matter for medication-error risk with a new liquid presentation, but the records do not show whether any apply here.

What to watch

The first step is to obtain the approved label and FDA review documents. These will show the indication, dosing, excipients, and any postmarketing requirements, none of which are in the records.

Other items to track are the commercial launch timing and the product's availability and labelling in practice. The records give none of these, and no timelines are implied. They also do not show any EU or other regional filings, so any such plans would need to come from other sources.